Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

23
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
04/11/2014 04/14/2014 04/15/2014 04/16/2014 04/17/2014 Date
61.38(c) 58.27(c) 55.45(c) 62(c) 62.27(c) Last
176 661 292 648 224 810 394 128 211 902 Volume
-1.40% -5.07% -4.84% +11.81% +0.44% Change
More quotes
Company
MorphoSys AG is engaged in the development of antibodies for therapeutic, diagnostic, and research applications. It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec. The Partnered Discovery segment involves technologies for the generation of... 
Sector
Biotechnology
Calendar
04/29Earnings Release
Surperformance© rating of MorphoSys AG
Trading Rating : Investor Rating :
More about the company
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 62,0 M
EBIT 2014 -13,3 M
Net income 2014 -12,5 M
Finance 2014 317 M
Yield 2014 -
Sales 2015 81,8 M
EBIT 2015 5,87 M
Net income 2015 0,31 M
Finance 2015 305 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 18,3x
EV / Sales 2015 14,0x
Capitalization 1 454 M
More Financials
Latest news on MORPHOSYS AG
04/11 MORPHOSYS : Announcement of the Convening of the AGM in Munich/Germany on 23 May..
04/02 MORPHOSYS : Biametrics Successfully Finalizes Feasibility Study with MorphoSys i..
03/31 MORPHOSYS : to Present at Two Upcoming Investor Conferences
03/23 XENCOR : Posts 4th Quarter and Full Year 2013 Financial Results
03/03 MORPHOSYS AG : MorphoSys to Present at Four Upcoming Investor Conferences
03/03 MORPHOSYS AG : Ad hoc: MorphoSys to Start Share Buy-Back Program
03/03 MORPHOSYS AG : MorphoSys to Start Share Buy-Back Program
02/10 MORPHOSYS AG : MorphoSys to Present at Three Investor Conferences in February
01/08 MORPHOSYS AG : MorphoSys to Present at J.P. Morgan Healthcare Conference
2013 MORPHOSYS AG : MorphoSys Announces Additional Clinical Trial of MOR208
2013 MORPHOSYS AG : MorphoSys Strengthens European Patent Position on anti-CD19 Cance..
2013 MORPHOSYS AG : Strengthens European Patent Position on anti-CD19 Cancer Program ..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
MorphoSys AG : Income Statement Evolution
More Financials
EPS Revisions
MorphoSys AG : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF